Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/9640
Title: Tranilast attenuates vascular hypertrophy, matrix accumulation and growth factor overexpression in experimental diabetes.
Authors: Bonnet, Fabrice;Cao, Zemin;Cooper, Mark E;Cox, Allison J;Kelly, D J;Gilbert, Richard E
Affiliation: Department of Medicine, University of Melbourne, Austin & Repatriation Medical Centre, Heidelberg West, Victoria. fab.so.bonnet@free.fr
Issue Date: 1-Sep-2003
Citation: Diabetes & Metabolism; 29(4 Pt 1): 386-92
Abstract: The growth factors transforming growth factor-B (TGF-B) and epidermal growth factor (EGF) have both been implicated in the hypertrophic structural changes in the vasculature that are characteristic features of both human and experimental diabetes. Recently, tranilast (N(3,4-dimethoxycinnamoyl)anthranilic acid), a drug used in the treatment of allergic and dermatological diseases, has also been reported to inhibit transforming growth factor-B (TGF-B)-mediated collagen formation. However, its effects on vascular hypertrophy in diabetes are unknown. The present study thus sought to determine the effects of tranilast on both TGF-B and EGF expression and mast cells in mediating the trophic vascular changes in experimental diabetes.Vessel morphology, growth factors and collagen gene expression and matrix deposition were examined in the mesenteric arteries of control rats treated with or without tranilast, and streptozotocin-induced diabetic Sprague-Dawley rats treated with or without tranilast (200 mg/kg/day) during a 3-week period.Compared with control animals, diabetic rats had significantly increased vessel weight, wall: lumen ratio, ECM accumulation, gene expression of TGF-B1, EGF, and both alpha1 (I) and alpha1 (IV) collagen. Tranilast treatment did not influence plasma glucose or systemic blood pressure. However, tranilast significantly reduced mesenteric weight, wall: lumen ratio and matrix deposition and also attenuated the overexpression of TGF-B1, EGF, and both alpha1 (I) and alpha1 (IV) collagen mRNA in diabetic rats.These findings indicate that tranilast ameliorates pathological vascular changes observed in experimental diabetes in association with reduced growth factor expression independent of blood glucose or systemic blood pressure.
Internal ID Number: 14526266
URI: http://ahro.austin.org.au/austinjspui/handle/1/9640
URL: http://www.ncbi.nlm.nih.gov/pubmed/14526266
Type: Journal Article
Subjects: Animals
Base Sequence
Blood Vessels.drug effects.pathology
Collagen.genetics
DNA Primers
Diabetes Mellitus, Experimental.complications
Diabetic Angiopathies.prevention & control
Epidermal Growth Factor.genetics
Gene Expression Regulation.drug effects
Growth Substances.genetics.metabolism
Hypertrophy
Immunohistochemistry
Male
Platelet Aggregation Inhibitors.therapeutic use
Rats
Rats, Sprague-Dawley
Reverse Transcriptase Polymerase Chain Reaction
Transforming Growth Factor beta.genetics
ortho-Aminobenzoates.therapeutic use
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.